

# CLAREON® VIVITY® AND CLAREON® VIVITY® TORIC IOLS

TECHNICAL SPECIFICATIONS: HIGH-ENERGY-VISIBLE-LIGHT-FILTERING (BLF)

Physical Characteristic	Description				
IOL Name	Clareon® VIVITY® IOL		Clareon® VIVITY® Toric IOL		
IOL Model	CNWET0	CNWET3	CNWET4	CNWET5	CNWET6
IOL Cylinder Powers at IOL Plane (diopters)	N/A	1.50	2.25	3.00	3.75
Corneal Plane (D)	N/A	.97D	1.46D	1.95D	2.44D
Optic Type	Wavefront-shaping EDoF (X-WAVE™ Technology) Biconvex Aspheric / Wavefront-shaping EDoF (X-WAVE™ Technology) Biconvex Aspheric Toric				
Optic and Haptic Material	Hydrophobic Acrylate / Methacrylate Copolymer <sup>1</sup>				
IOL Powers (spherical equivalent diopters)	+10.0 D to +30.0 D (available in 0.5D Increments)*				
Index of Refraction	1.55 <sup>1</sup>				
<b>Haptic Configuration</b>	STABLEFORCE® Modified-L Haptics <sup>1</sup>				
Optic Diameter (mm) Ø	6.0 <sup>1</sup>				
Overall Length (mm) Ø	13.0 <sup>1</sup>				
Haptic Angle	0° <sup>1</sup>				
Asphericity (µm)	-0.2 <sup>2</sup>				
Position	Planar (posterior optic edge is aligned with posterior haptic edge)				
IOL Constants <sup>1-5</sup>	<b>Formula</b>	<b>Optical Coherence</b>		<b>U/S Biometry<sup>‡</sup></b>	
	SRK/T A-Constant S	119.2 <sup>†</sup>		118.8	
	Holladay I (S factor)	1.90		1.68	
	Holladay II (ACD)	5.67		5.43	
	Hill-RBF	119.15		118.8	
	Hoffer Q	5.67		5.43	
	Barrett	1.99		1.78	

\*Further Toricity Powers will be available at a later date

<sup>†</sup>Clinically validated

<sup>‡</sup>Theoretical

## IMPORTANT PRODUCT INFORMATION:

### CLAREON® VIVITY® FAMILY OF EXTENDED VISION IOLS

**CAUTION:** Federal (USA) law restricts this device to the sale by or on the order of a physician.

**INDICATIONS:** The **Clareon® Vivity® Extended Vision Hydrophobic Posterior Chamber IOLs** include **Clareon® Vivity®** and **Clareon® Vivity® Toric IOLs** and are indicated for primary implantation for the visual correction of aphakia in adult patients with <1.00 D of preoperative corneal astigmatism, in whom a cataractous lens has been removed by extracapsular cataract extraction. The lens mitigates the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the lens provides improved intermediate and near visual acuity, while maintaining comparable distance visual acuity. The **Clareon® Vivity® IOL** is intended for capsular bag placement only. In addition, the **Clareon® Vivity® Toric IOL** is indicated for the reduction of residual refractive astigmatism in adult patients with pre-existing corneal astigmatism.

**WARNINGS / PRECAUTIONS:** Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk / benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling.

This lens should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary, lens repositioning should occur as early as possible prior to lens encapsulation.

Most patients implanted with the **Clareon® Vivity® IOL** are likely to experience significant loss of contrast sensitivity as compared to a monofocal IOL. Therefore, it is essential that prospective patients be fully informed of this risk before giving their consent for implantation of the **Clareon® Vivity® IOL**. In addition, patients should be warned that they will need to exercise caution when engaging in activities that require good vision in dimly lit environments, such as driving at night or in poor visibility conditions, especially in the presence of oncoming traffic.

It is possible to experience very bothersome visual disturbances, significant enough that the patient could request explant of the IOL. In the parent AcrySof® IQ Vivity® IOL clinical study, 1% to 2% of AcrySof® IQ Vivity® IOL patients reported very bothersome starbursts, halos, blurred vision, or dark area visual disturbances; however, no explants were reported.

Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon informing them of possible risks and benefits associated with the **Clareon® Vivity® IOLs**.

**ATTENTION:** Reference the Directions for Use labeling for each IOL for a complete listing of indications, warnings, and precautions.

**References:**

1. Clareon® IOL Directions for Use.
2. Alcon Data on File. 2015.
3. Holladay JT. Standardizing constants for ultrasonic biometry, keratometry, and intraocular lens power calculations. *J Cataract Refract Surg.*1997;23:1356-1370.
4. Barrett Universal II Formula V1.05. APACRS. Available from: [https://calc.apacrs.org/barrett\\_universal2105/](https://calc.apacrs.org/barrett_universal2105/).
5. Clareon® Monarch® IV IOL Delivery System Directions for Use.



**Alcon**